VERVE-102: a one-time gene edit for cholesterol, and why it's a brain story.
Most people learn their cholesterol is high at an annual physical, get told to watch it, and never find out what the number means. In midlife, high cholesterol can mean increased brain health risk.
A single infusion lowered LDL cholesterol by up to 62% and held it there for 18 months. It is years from a clinic. The target it aims at, your lipid health, is something you can measure and move today.
What VERVE-102 actually did
Heart-2 is a phase 1b trial. The interim analysis covered 35 participants, average age 52, all with heterozygous familial hypercholesterolemia, premature coronary artery disease, or both, and all already on the maximum statin dose they could tolerate. Each received one infusion, at doses from 0.3 to 1.0 mg/kg. PCSK9 protein fell by 51% to 88% depending on dose, and LDL cholesterol fell by 9% to 62%. The results were presented at the European Atherosclerosis Society Congress and published in the New England Journal of Medicine.
There were no dose-limiting toxicities and no treatment-related serious adverse events. Side effects were mostly low-grade infusion reactions and fatigue. All 35 participants received their full dose and none withdrew.
How PCSK9 works, in plain language
Your liver clears LDL cholesterol out of your blood using surface proteins called LDL receptors. Think of them as docking ports: the more ports available, the more LDL particles get pulled out of circulation. PCSK9 is a protein that destroys those ports. More PCSK9 activity means fewer receptors, which means more LDL staying in your bloodstream.
Some people are born with naturally low-functioning PCSK9 genes. They have markedly lower LDL across their entire lives and substantially lower rates of heart disease, with no apparent downside. Turning PCSK9 down is not a theory. It is a protective pattern that already exists in nature and has been studied for two decades.
Drugs that lower PCSK9 have been approved for years. What is new here is the delivery. VERVE-102 uses base editing, a precise form of gene editing, to make a single change to the PCSK9 gene inside liver cells. The goal is to do once, permanently, what existing drugs do by repeated injection.
That stage tests safety in a small number of people. It has not been shown to prevent heart attacks, strokes, or cognitive decline.
Everyone enrolled had an inherited form of very high cholesterol or early coronary artery disease. These are not general-population results.
Making a permanent edit to a gene is still new, and the long-term safety record takes years to build.
Nobody should be adjusting their plan today on the expectation that this arrives soon.
Why cholesterol is a brain story, not only a heart story
Brain health is whole-body health, and few things connect the two as directly as lipids. You have probably heard of LDL cholesterol. ApoB is the more precise measurement sitting beneath it.
Every LDL particle carries exactly one ApoB protein. LDL-C tells you how much cholesterol is being carried. ApoB tells you how many particles there actually are. Since it is the particles that lodge in artery walls and start plaque, ApoB is the better predictor of risk. When the two numbers disagree, ApoB is the one to trust.
ApoB is the single most commonly out-of-range marker we see. It is not part of a standard lipid panel, so most people have never had it measured.
The Lancet Commission added LDL to the dementia list in 2024
The blood vessels feeding your brain are subject to the same lipid-driven damage as the ones feeding your heart, and that vascular damage is one of the major pathways of cognitive decline. In its 2024 update, the Lancet Commission added high midlife LDL cholesterol as one of 14 modifiable risk factors, based on cohort studies covering more than a million participants plus a Mendelian randomization meta-analysis of 27 studies. The Commission attributes 7% of preventable dementia to high LDL alone, and links nearly half of dementia cases to the 14 factors combined.
If you carry APOE4
People who carry an APOE4 variant tend to run higher LDL, and APOE4 is the strongest common genetic risk factor for Alzheimer's disease. That combination is one reason lipid management is a core part of what we do, and one reason knowing your genotype can change what you prioritize rather than just giving you something to worry about.
The bigger picture
Between therapies like this one and the medications already on the shelf, the tools for managing cardiovascular disease are getting very good, and they will keep improving. But adding years to your life is only worth so much if your brain is not working well for those years. That is the conversation most people are not having yet, and it is the one that matters most to us.
What this means for you, right now
A routine lipid panel gives you total cholesterol, LDL, HDL, and triglycerides. ApoB counts the particles actually driving damage and is rarely ordered unless you ask for it.
The PCSK9 story works precisely because it lowers exposure over decades. Risk accumulates the same way. Small, steady improvements compound in your favor, and starting earlier is worth more than starting perfectly.
Diet, regular movement, and, where your physician recommends them, proven lipid-lowering medications all work today. Statins and existing PCSK9 inhibitors are not placeholders waiting for gene editing. They are the current standard of care.
ApoB, Lp(a), triglycerides, blood pressure, and HbA1c interact. One number in isolation rarely tells you what to do first.
Common questions
No. VERVE-102 is in phase 1b trials. A phase 2 trial is planned to begin enrolling by the end of 2026, and broad availability is years out. If it is approved, the first patients are likely to be people with familial hypercholesterolemia or other very high-risk conditions.
LDL-C measures the amount of cholesterol carried inside LDL particles. ApoB measures the number of those particles, because each one carries exactly one ApoB protein. Two people can have the same LDL-C with very different particle counts. When the two disagree, ApoB is the better predictor of cardiovascular and cerebrovascular risk.
The 2024 Lancet Commission identified high midlife LDL cholesterol as one of 14 modifiable dementia risk factors and attributes 7% of preventable dementia to it. That is an association drawn from large cohort and genetic studies, not proof that lowering LDL prevents dementia in any individual. What is well established is that lipid-driven damage to blood vessels is one of the major pathways of cognitive decline.
ApoB is not part of a standard lipid panel and usually has to be requested. It is most informative if you have a family history of early heart disease or dementia, if your LDL and triglycerides do not line up, if you carry an APOE4 variant, or if you simply want a clearer read than total cholesterol gives you. Discuss it with your physician or your Brain Health Coach.
Yes. ApoB is included in the BetterBrain biomarker panel, which covers 50+ markers selected for their connection to brain health, across metabolic, cardiovascular, hormonal, inflammation, and nutrient categories. Blueprint is $89 with insurance and $399 without, and includes a cognitive assessment and an up-to-90-minute session with a Brain Health Coach.
Take control of your brain health today
The Coaching Program pairs you with a dedicated Brain Health Coach, $0 with insurance for eligible clients. Want the data first? ApoB is one of 50+ markers in the Blueprint panel, $89 with insurance, $399 without. Either way you get lifetime access to the BetterBrain app, including your dashboard, resources, SMS support, and 24/7 access to BeBe, the AI coach.
High LDL in midlife is now on the dementia risk list.
Most people have never had the number underneath it measured. ApoB, the particle count under LDL, is something you can check this month.
Most people have never had it measured
A routine lipid panel gives you total cholesterol, LDL, HDL and triglycerides. ApoB counts the particles actually driving damage, and is rarely ordered unless you ask for it. It is the single most commonly out-of-range marker we see across BetterBrain clients.
ApoB counts particles, not cholesterol
Every LDL particle carries exactly one ApoB protein. LDL-C tells you how much cholesterol is being carried. ApoB tells you how many particles there actually are. Since it is the particles that lodge in artery walls and start plaque, ApoB is the better predictor of risk. When the two disagree, ApoB is the one to trust.
The Lancet added LDL to the dementia list in 2024
The blood vessels feeding your brain take the same lipid-driven damage as the ones feeding your heart, and that vascular damage is one of the major pathways of cognitive decline. The Commission attributes 7% of preventable dementia to high LDL alone, and links nearly half of dementia cases to the 14 factors combined.
A coach turns the number into a plan
A dedicated Brain Health Coach turns your numbers into a personalized action plan, ranked by impact, and works through it with you week by week. 92% of eligible clients pay $0.
High midlife LDL is an association drawn from large cohort and genetic studies, not proof that lowering it prevents dementia in any one person. What is well established is that lipid-driven damage to blood vessels is a major pathway of cognitive decline, and that the vessels feeding your brain are affected the same way as the ones feeding your heart. Whatever arrives in five or ten years, the decades in between are the ones you protect now.
One number you can measure, and move.
Start with a Brain Health Coach, $0 with insurance for eligible clients. Add the 50+ marker panel including ApoB when you are ready, $89 with insurance, $399 without. You keep lifetime access to the BetterBrain app and to BeBe, the AI coach, after the program.